NASDAQ$KROS
Keros Therapeutics Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Keros Therapeutics reported financial results for the third quarter of 2020.
Keros Therapeutics reported a net loss of $12.0 million in the third quarter of 2020. Research and development expenses were $8.4 million, and general and administrative expenses were $3.6 million. Cash and cash equivalents as of September 30, 2020, were $133.8 million.
- Dosed the first patients in Phase 2 clinical trial of KER-050.
- Regained worldwide rights to development programs in metabolic diseases.
- Completed expanded Phase 1 clinical trial of KER-047.
- Expects to have multiple ongoing Phase 2 clinical trials in 2021.
Headline financials
Revenue & EPS history
Keros · Revenue · Quarterly
$0
Forward guidance
Keros expects that the cash and cash equivalents it had on hand at September 30, 2020 will fund its operating expenses and capital expenditure requirements into the second half of 2022.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
+0.4%
Avg return
Earnings day
+0.1%
Avg return
5 days after
+5.0%
Avg return
30 days after
42%
10 / 24 earnings
Positive
+34.0%
Q3 2021
Best reaction
-15.0%
Q4 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q1 2026 | -8.5% | -17.4% | -15.4% | |
| Q4 2025 | -15.0% | -15.9% | -12.9% | |
| Q3 2025 | +3.4% | +8.0% | +38.6% | |
| Q1 2025 | +0.7% | +0.1% | -3.3% | |
| Q4 2024 | +0.6% | +5.9% | -1.4% | |
| Q3 2024 | +7.3% | +8.9% | +11.9% | |
| Q2 2024 | -8.9% | -8.0% | +7.7% | |
| Q1 2024 | -1.8% | -8.0% | -17.0% | |
| Q4 2023 | -3.6% | -1.4% | -5.4% | |
| Q3 2023 | -0.3% | -7.4% | +4.8% | |
| Q2 2023 | -10.3% | -12.9% | -12.9% | |
| Q1 2023 | -2.6% | -2.3% | +8.6% | |
| Q4 2022 | -6.4% | -3.6% | -23.4% | |
| Q3 2022 | -2.0% | -9.2% | +3.2% | |
| Q2 2022 | +14.7% | +13.5% | +10.6% | |
| Q1 2022 | -12.5% | -15.5% | -36.5% | |
| Q4 2021 | +8.7% | -3.5% | +29.9% | |
| Q3 2021 | +34.0% | +43.0% | +30.3% | |
| Q2 2021 | +5.5% | +2.6% | -3.7% | |
| Q1 2021 | -2.4% | -6.9% | -13.5% | |
| Q4 2020 | +4.4% | +6.6% | +14.0% | |
| Q3 2020 | -0.9% | +8.1% | +41.4% | |
| Q2 2020 | +7.1% | +12.8% | +23.6% | |
| Q1 2020 | -2.0% | +4.0% | +41.0% | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro